India’s largest drug maker Dr Reddy’s Laboratories has announced the launched of ‘Sodium Nitroprusside injection,’ in the U.S. market for immediate reduction of blood pressure in hypertensive crises.
In a filing at the BSE, Dr Reddy’s Lab said: “The company has launched the generic Sodium Nitroprusside injection, 50mg/2 ml (25 mg/ml) single-dose vial, the therapeutic generic equivalent of Nitropress (sodium nitroprusside) Injection, 5 mg/2ml vials, in the U.S. market after getting the approval from the U.S. Food and Drug Administration (USFDA).”
“The Nitropress brand and generics had U.S. sales of approximately $8 million MAT for the most recent twelve months ending in October 2019 according to IQVIA Health,” the filing added.
“Sodium Nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises,” the statement further added.
